Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
The Gift of Knowing Your Family Health History
August 8th 2019In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Allyn Rose, the first woman who had undergone a mastectomy to be featured by Sports Illustrated, about her family history with cancer and her advocacy work with the AIRs Foundation.
Read More
FDA Grants Priority Review to Tazemetostat for Epithelioid Sarcoma
July 25th 2019The Food and Drug Administration granted a priority review to a new drug application for the accelerated approval of tazemetostat to treat metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Read More
FDA Approves Biosimilar Ruxience: Here's What You Need to Know
July 24th 2019With the Food and Drug Administration’s approval of Ruxience, a biosimilar to Rituxan, patients with certain types of non-Hodgkin lymphoma and chronic lymphocytic leukemia may have improved access to a more affordable treatment option.
Read More
Updated Analysis Supports Evaluation of Second-Line Fedratinib to Treat Myelofibrosis
July 24th 2019Treatment with fedratinib may lead to clinically meaningful responses among patients with myelofibrosis who were previously treated with Jakafi, according to an updated analysis of the phase 2 JAKARTA2 study.
Read More